Background. Although Clostridium difficile infections (CDIs) are increasingly diagnosed in children, many children diagnosed with CDI lack classic risk factors. Frequent use of highly sensitive tcdB polymerase chain reaction (PCR) testing in low-risk patients leads to CDI misdiagnosis and unnecessary CDI antibiotic use in children with C difficile carriage.
Accurately diagnosing Clostridium difficile infection (CDI) is challenging. Several unique diagnostic assays are available, and these vary significantly in cost, ease of performance, turnaround time, and specificity and sensitivity [1] . For these reasons, the preferred assay for CDI diagnosis varies among adult healthcare facilities [1] . Because of rapid turnaround time and high sensitivity, approximately half of adult hospitals [1] and two thirds of children's hospitals [2] utilize a nucleic acid amplification test (NAAT), such as polymerase chain reaction (PCR), as their primary method for diagnosing CDI. Nucleic acid amplification tests are limited by their inability to differentiate CDI from asymptomatic carriage, leading to discordance between analytic and clinical specificity [3, 4] .
Overdiagnosis of CDI in adults in the NAAT era has been described [4] . A substantial proportion of adult patients diagnosed with CDI lack diarrhea, have clinically insignificant diarrhea (ie, fewer than 3 unformed stools in a 24-hour period), or have recently received laxatives [1, 5, 6] . Testing low-risk patients increases the likelihood of identifying C difficile carriers rather than CDI. Misdiagnosing CDI among carriers leads to unnecessary CDI antibiotic exposure and overestimation of hospital CDI rates, which are publically reported by many hospitals. Recommended strategies [7] for reducing CDI misdiagnosis among carriers include laboratory restriction of C difficile testing to unformed stools and limiting C difficile testing to once per diarrheal episode; the majority of adult [8] and pediatric [2] hospitals utilizing NAATs have instituted such policies. However, these policies will not prevent CDI misdiagnosis in a patient whose unformed stools are unlikely to be attributable to C difficile, such as those with probable viral gastroenteritis or those who are concomitantly receiving laxatives. Knowledge deficits among healthcare providers (HCPs) associated with CDI testing behaviors have been reported [9] .
Among pediatric patients, frequent asymptomatic carriage has been identified among infants and young children [10] , hospitalized children [11] , and children with cancer [12] or inflammatory bowel disease (IBD) [13] . This raises concerns about the reliability of PCR to identify patients with CDI among a population with frequent carriage. Since adopting PCR for C difficile diagnosis at our children's hospital in 2009, we observed annual increases in CDI frequency concomitant with increases in frequency of C difficile testing. Increased CDI frequency appeared to be driven by increased community-associated (CA) CDI, whereas healthcare facility-associated (HCFA) CDI rates have remained relatively stable. We have found that many children diagnosed with CDI at our institution likely have alternate etiologies for diarrhea, such as viral illnesses or laxative use [14] . To educate HCPs about the limitations of NAATs for the diagnosis of CDI and to potentially reduce CDI misdiagnosis related to HCP testing behaviors, we developed and implemented a HCP educational intervention (EI) to reduce unnecessary C difficile testing of patients with low likelihood of CDI. Clostridium difficile testing data were assessed pre-and postintervention to evaluate the impact of the EI on C difficile testing behaviors by HCPs.
METHODS

Study Setting
This quasi-experimental study was performed at the Ann & Robert H. Lurie Children's Hospital of Chicago, a 288-bed tertiary care urban academic children's hospital. The Institutional Review Board (IRB) at Lurie Children's confirmed that this study was exempted from IRB review because of the use of deidentified laboratory informatics data to evaluate this EI.
Polymerase chain reaction was adopted as the sole method for CDI testing in the clinical microbiology laboratory in August 2009. Active surveillance for hospital-onset (HO) and community-onset (CO) HCFA CDI has been an ongoing infection prevention and control activity that predates the change to PCR testing for CDI. Lurie Children's laboratory-identified HO-and CO-HCFA CDI incidence density data have been reported monthly to the National Healthcare Safety Network (NHSN) since May 2011. The infection prevention and control team does not perform active surveillance for CA-CDI.
Intervention
A multifaceted EI was implemented in September 2013. At that time, laboratory policies were already in place that restricted C difficile testing to unformed stools collected from children who are at least 12 months old and who had not been tested for CDI in the past 7 days. Although these policies predate the transition to tcdD PCR in 2009, to ensure continued compliance with these policies, and to instruct clinical microbiology technologists on how best to provide direct feedback to HCPs when rejecting a specimen for CDI testing, the EI included a 30-minute presentation to hospital clinical microbiology technologists by a pediatric infectious diseases fellow (Table 1 ). In the electronic medical record (Epic, Verona, Wisconsin), we incorporated a notification into the C difficile PCR test order menu that advised the ordering HCP regarding judicious use of this test (Table 2 ). This notification was initiated in September 2013 and remained in place throughout the intervention and postintervention period. In December 2013 and January 2014, we also provided didactic education to 5 groups of hospital HCPs during their regularly scheduled educational conferences (Table 1) : pediatric housestaff; pediatric advanced practice nurses; pediatric hematology/oncology/stem cell transplant clinicians; pediatric emergency medicine clinicians; and pediatric solid organ transplant clinicians. Groups of HCPs were chosen for this intervention based on the frequency of C difficile testing among their respective patient populations, the volume of clinical care they provide to pediatric patients, and their willingness to participate in additional didactic education.
Data Collection and Definitions
Electronically extracted C difficile testing data included the test date, test order location, and test result. We calculated the total number of C difficile PCR tests processed by the laboratory and the total number of positive and negative C difficile PCR tests each month. Testing data were further grouped by test location (ie, inpatient, emergency department [ED], or non-ED outpatient locations). For patients who were subsequently transferred, the location from which the test was ordered determined the group to which it was assigned. Hospital financial records provided the total monthly inpatient, ED, and outpatient encounters (ie, the sum of which includes all medical center patient encounters and is referred to as aggregate patient encounters).
Table 1. Topics Included in the Healthcare Provider Didactic Education
Topics Included in 15-Minute Clinician Didactic Education
• Epidemiology of Clostridium difficile infection (CDI) and asymptomatic carriage
• C difficile polymerase chain reaction test interpretation
• American Academy of Pediatrics recommendations for CDI testing [19] • Hospital CDI surveillance and C difficile testing data
• Impact of CDI misdiagnosis on patient care and hospital CDI surveillance
• Suggestions for improving CDI testing behaviors
• Questions and answers
Additional Topics Included in 30-Minute Microbiology Technologist Didactic Education
• Review of criteria for rejecting specimens for CDI testing
• Guidance for responding to healthcare provider inquiries after specimen rejection Aggregate C difficile testing rate (TR) and aggregate C difficile test positivity rate (PR) were calculated as number of C difficile tests processed per 1000 aggregate patient encounters and number of positive C difficile tests per 1000 aggregate patient encounters, respectively. Testing rates and PRs in the inpatient, ED, and outpatient settings were each individually calculated as number of C difficile tests processed and number of positive C difficile tests originating from each setting, respectively, per 1000 setting-specific patient encounters. The proportion of tests processed by the laboratory that were positive for C difficile was calculated.
Clostridium difficile infection cases were classified as HO-HCFA, CO-HCFA, and CA using standard definitions [15] . Specifically, HO-HCFA is defined as symptom onset in the hospital and at least 48 hours after admission; CO-HCFA is defined as symptom onset in the community (or within 48 hours after hospital admission) provided the patient had been hospitalized in the previous 4 weeks; CA is defined as symptom onset in the community (or within 48 hours after hospital admission) provided the patient had not been hospitalized in the previous 12 weeks. Hospital laboratory-identified HO-and CO-HCFA CDI incidence density (ie, CDI cases per 10 000 patient days) were classified according to NHSN criteria [16] .
Analysis
The above data were calculated monthly throughout the 49-month preintervention period (August 2009-August 2013) and the 18-month postintervention period (February 2014-July 2015). All analyses excluded data between September 2013 (when the electronic medical record prompt was implemented) and January 2014 (when didactic education was completed). We used a series of segmented regression analyses of interrupted time series data [17] to assess differences in level (ie, overall rates) and trend (ie, changes in monthly rates over time) of rate data between the pre-and postintervention periods. Using generalized estimating equations and the empirical standard error ("sandwich" estimator), we constructed a series of generalized linear models with negative binomial distributional assumptions (to account for overdispersion in Poisson models) and log link for count data. Two-sided P values < .05 were considered statistically significant. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina). Estimates of CDI-related patient charges following the EI are described in the Supplementary Data.
RESULTS
Numbers of monthly patient encounters, C difficile tests processed, and positive C difficile tests are summarized in Table 3 , and the C difficile TR and PR data are listed in Table 4 . After the EI, we observed a significant reduction in the level of the aggregate TR, outpatient TR, and outpatient PR (Table 4 and Figure 1 ), as well as the ED TR (Table 4 and Supplementary  Figure 1) . The observed trend of rising aggregate TR, aggregate PR, outpatient TR, and outpatient PR in the pre-EI period was significantly interrupted by the EI (Table 4 and Figure 1 ). After the EI, there were no significant changes in TR or PR in the inpatient setting (Table 4 and Supplementary Figure 1) and no significant changes in the NHSN-reported laboratory-identified HO-and CO-HCFA CDI rates (Table 4 and Supplementary  Figure 2) . The C difficile test positivity proportions in the preand postintervention periods, respectively, were 0.18 and 0.17 (P = .75) in aggregate; 0.20 and 0.15 (P = .26) in the outpatient setting; 0.15 and 0.16 (P = .15) in the inpatient setting; and 0.22 and 0.24 (P = .40) in the ED.
The aggregate absolute rate reduction for TR was 0.71 tests/1000 patient encounters. Thus, the EI was associated with a reduction of 574 tests, resulting in an estimated patient charge savings of $211 232 for C difficile tests during the 18-month postintervention period. The aggregate absolute rate reduction for CDI PR was 0.14 positive tests/1000 patient encounters.
Table 2. Electronic Medical Record Prompt When Ordering Clostridium difficile Polymerase Chain Reaction (PCR) Testing
Because C difficile PCR is highly sensitive and frequently identifies colonized patients, testing should NOT be ordered for patients with low probability of infection, such as the following:
• A patient without risk factors who has vomiting as a significant complaint.
• The stool is soft or formed.
• A patient has diarrhea and is prescribed stool softeners or laxatives.
• The test is ordered as a "test of cure" after treatment.
• A negative C difficile PCR result was reported within the last 7 days. Thus, we observed 113 fewer positive tests and subsequent courses of antibiotics for CDI during the postintervention period. Estimated savings in patient charges for CDI antibiotic therapy during the 18-month postintervention period ranged from $13 110 for suspension and $43 941 for capsules/tablets.
DISCUSSION
The results of this quasi-experimental study demonstrate that a multifaceted EI for HCPs is associated with reduced C difficile testing in a cohort of pediatric patients. The most substantial declines in C difficile TR and PR occurred among children evaluated for CDI in the outpatient setting. Because active surveillance for CA-CDI is not an infection prevention and control activity at our facility, specific CA-CDI rates were not available. However, because HO-and CO-HCFA CDI rates were unchanged during the study period, the reduction in CDI PR can be inferred to be predominantly among patients without hospitalization in the previous 4 weeks. We have previously reported that compared with children with HO-HCFA CDI, children with CA-CDI are significantly less likely to have risk factors for CDI, including malignancy, gastrostomy tube, and recent antibiotic or proton-pump inhibitor exposure [14] . Thus, because the intervention was associated with a significant reduction in CDI testing among patients in the outpatient setting, it can be inferred that patients at lower risk of CDI were most impacted by the intervention. With increasing use of rapid molecular tests, particularly highly sensitive tests with discordant analytic and clinical specificity, efforts to guide appropriate use of laboratory tests can serve as an important adjunct to antibiotic stewardship programs. Reducing CDI misdiagnosis among carriers can reduce unnecessary antibiotic exposure to treat those infections, potentially reducing antibiotic resistance and adverse events. Furthermore, there may be additional repercussions associated with false-positive tests, such as unnecessary patient and/or parent anxiety; unnecessary hospital isolation and use of personal protective equipment; delays in identification of the correct diagnosis; and inaccurate hospital-associated infection surveillance rates, which may be publicly reported and impact reimbursement. Because of the potential impact of unnecessary testing on patient care and healthcare expenditures, new diagnostic strategies require thoughtful implementation to limit these unintended consequences.
Our findings suggest that the EI had a relatively limited impact in the ED setting. Potential explanations for this observation include the wide variability in the acuity and complexity of children evaluated in the ED setting. In addition, the ED at our institution is frequently staffed by visiting non-pediatric (eg, emergency medicine and family medicine) housestaff from other institutions who did not receive didactic education and whose approach to CDI may be biased by their experience providing care to adult patients at their home institutions. Because CDI is an uncommon cause of diarrhea in the pediatric ED setting and is often identified concomitantly with other gastrointestinal viruses [14, 18] , the ED HCPs may benefit from ongoing education.
The EI did not appear to significantly impact the proportion of tests that were positive for C difficile. If it were true that the likelihood of C difficile positivity was higher among children with diarrhea compared with asymptomatic controls, then more discriminatory testing could be hypothesized to lead to an increased proportion of positive tests. However, even among populations of children with risk factors for CDI, toxigenic C difficile is identified in very high proportions of asymptomatic children. For example, asymptomatic C difficile carriage recently has been reported among 29% of children with cancer [12] ; 17% of children with IBD [13] ; and 24% of hospitalized children [11] . Furthermore, the proportions of children testing positive for C difficile are often very similar among children with and without diarrhea [11, 19] . Thus, it is not surprising that CDI test positivity proportions did not change after the intervention. This further supports the need to restrict testing in children with low CDI pretest probability and to base testing decisions on clinical significance of diarrhea, CDI risk factors, and degree of suspicion for other diarrheal etiologies. The estimated impact of the EI on patient care and hospital charges was substantial. We estimate the EI prevented processing of 574 CDI tests by the clinical microbiology laboratory (approximately 1 test per day) and avoided 113 positive tests (and subsequent prescriptions for CDI antibiotic therapy) during the 18-month postintervention period. This resulted in a reduction of CDI-related patient charges of approximately $250 000 for testing and treatment during the postintervention period. This is particularly impressive considering the relatively low cost and effort required to implement the EI. The didactic education was developed and implemented by a pediatric infectious diseases fellow with a particular interest in healthcare epidemiology and pediatric CDI. The time commitment for face-to-face meetings for infectious diseases, infection prevention and control, and clinical microbiology team members was minimal. Hospital clinical informatics staff built the electronic medical record notification as part of their routine employment activities.
Hospital charge data may not accurately estimate healthcare costs, and charge-to-reimbursement ratios vary considerably among hospitals [20] . Clostridium difficile infection-related hospital charges are reported here primarily because they are fixed charges irrespective of payer and healthcare setting (inpatient vs outpatient). Reimbursement for all charges during a patient encounter is often bundled, and determining the reimbursement specifically for CDI-related tests and treatment is challenging. For example, for all outpatients who were tested for CDI at our hospital in fiscal year 2015, the average reimbursement was 27% of all charges from those visits, and reimbursement varied considerably among payers (ranged 0%-100%).
Because of the consistently rising CDI TR for several years preceding the EI, and because of the immediate change in the level and trend of TR observed after the EI, the findings of this quasi-experimental study strongly suggest that the EI contributed to the decline in CDI testing in the postintervention period. However, a cluster randomized trial would strengthen this assertion. It is unclear which particular components of the multifaceted EI were most effective for reducing CDI testing. The reduction in TR remained low and continued to decline at the latter part of the postintervention period in the aggregate, inpatient, and outpatient settings. This suggests that the electronic medical record notification, which was an ongoing intervention starting in September 2013, may have lasting impact. An additional limitation of this study is the inability to assess potential harm to patients related to avoidance of appropriate testing in a patient with CDI. Deferred testing could potentially lead to delayed therapy and progression of CDI in the interim. The intervention was designed to focus on the care of well appearing children and/or children with well established clinical indicators associated with CDI overdiagnosis (eg, clinically insignificant diarrhea, laxative use, a recent negative PCR test, and features such as vomiting that are more consistent with viral gastroenteritis). The limited impact of the EI on the rate of CDI testing among inpatients supports this. For these reasons, we believe the EI was associated with minimal unintended harm to patients.
Poor clinical specificity for identification of patients with CDI is primarily an issue with NAATs, whereas toxin-based assays better discriminate patients with CDI and asymptomatic carriers [3, 4] . Because NAATs have not been adopted at all healthcare facilities, this intervention is not generalizable to all hospitals. However, because of reported suboptimal sensitivity of toxin-based assays [1] , approximately half of adult hospitals [1] and two thirds of children's hospitals [2] utilize NAATs as their primary method for diagnosing CDI. Thus, many hospitals may benefit from implementing a similar intervention.
CONCLUSIONS
In conclusion, our findings suggest that a multifaceted HCP EI can successfully reduce CDI testing among children at low risk for CDI. This reduction in CDI testing is associated with substantial estimated savings in patient charges from averted CDI tests and subsequent unnecessary courses of antibiotics for CDI. This model may also be effective for improving the utilization of other microbiologic tests, which will become increasingly important with the expanding commercial availability of highly sensitive molecular tests for many infectious diseases. However, optimal diagnosis of CDI in children ultimately requires an adequately sensitive CDI diagnostic test that better differentiates CDI and asymptomatic carriage.
